Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
about
Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studiesEfficacy and safety of tofacitinib for treatment of rheumatoid arthritis.Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysisTreatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of TuberculosisExtended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.Current landscape for T-cell targeting in autoimmunity and transplantation.JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth.A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib.Stimulation of human TRPA1 channels by clinical concentrations of the antirheumatic drug auranofin.[Janus kinase inhibitors].Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.Tofacitinib
P2860
Q26772850-78F41A69-9196-4E50-8EDB-D8C78E03F682Q34047746-E7F0329A-5363-435F-81D5-81B1D5214AF8Q34677487-29F70631-A3A1-4F33-B04B-CF369B0BB586Q34858352-A9A795DB-B826-4AB4-9DDE-2E6626555581Q35092982-F5853995-B088-4210-AC56-EFDF1C45CE5EQ36010298-A7B9C15A-05E6-4CFF-B3D6-5312D6BACDABQ36038705-01C3C52A-C40D-4A16-A717-6CABAD004D7EQ37420530-A3C2F976-8BF8-4EB6-AFD8-A879E61131B8Q37562464-A9FB2C8B-686F-4084-8020-7164CBFC9327Q37900647-D3D6E385-F685-4258-AC2E-06AF3376F5F1Q37926574-13893AB1-6F55-44FF-860C-E3AD3AA44451Q38097494-3B309DA7-E602-497F-B784-952E61A5A24FQ38110227-A9C62B78-F820-4312-A5E0-AADE19FC5885Q38604390-9832569A-E38D-4ED8-801E-15920BB115EDQ42713895-EA57786D-57F9-46A3-9D83-23E5600CC68BQ43963029-D68212FF-B59F-466C-9033-0E837510CC6EQ48933623-3E33F0A5-1F09-42A8-8C39-271F4A5CC4DDQ49232396-F3801594-BB71-44A9-BD3A-ABBC7EB6AD61Q54312411-E13D3560-C1B1-4E3E-AAE6-9A89DB525827Q56852193-F28570AC-85B1-4EF7-80DC-647F6FFD0417
P2860
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Co-administration of the JAK i ...... hout need for dose adjustment.
@ast
Co-administration of the JAK i ...... hout need for dose adjustment.
@en
type
label
Co-administration of the JAK i ...... hout need for dose adjustment.
@ast
Co-administration of the JAK i ...... hout need for dose adjustment.
@en
prefLabel
Co-administration of the JAK i ...... hout need for dose adjustment.
@ast
Co-administration of the JAK i ...... hout need for dose adjustment.
@en
P2093
P2860
P1476
Co-administration of the JAK i ...... hout need for dose adjustment.
@en
P2093
Bethanie Wilkinson
Robert R Labadie
Samuel H Zwillich
Stanley Cohen
Vincent Chow
P2860
P304
P356
10.1111/J.1365-2125.2009.03570.X
P407
P577
2010-02-01T00:00:00Z